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Summary.-Measurements of methotrexate have been made in the liver and plasma
of 4 patients and in the bile and plasma of 1 patient receiving [3H]methotrexate.
Projections from a theoretical model of concentration of methotrexate in liver are
confirmed but projections of biliary excretion are not.
BISCHOFF and co-workers have de-
scribed a multicompartment mathematical
model for methotrexate (Mtx) pharma-
cokinetics (Bischoff, Dedrick and Zaharko,
1970: Bischoff et al., 1971: Zaharko et al.,
1971: Dedrick, Zaharko and Lutz, 1973).
The full model is somewhat complex and is
based on a series ofmass-balance equations
utilizing observed data, initiallH from the
mouse, but later extended to other species
and to man, and incorporating known
flow rates for the organs comprising the
compartments. The solution ofthis set of
simultaneous linear differential equations
comprises the description of Mtx pharma-
cokinetics. Forexample, the massbalance
equation for the kidney (see Zaharko et al.,
1971) is given by:
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where: V = organ wet weight. g, C = concentration,
ug g (or ml). t = time. min, Q = flow rate, ml/min,
R = tissue-to-plasma equilibrium, distribution ratio,
k = clearance, ml/min.
The subscript K and P refer respec-
tivelv to kidnev and plasma. The model
has been used to predict concentrations in
tissues in man after intravenous Mtx from
the plasma concentration data ofHender-
son, Adamson and Oliverio (1965). Since
it is an important part ofthe function ofa
pharmacokinetic model to predict for
data that are important to, but not
readily obtainable bv, the clinician using
the drug it is essential to determine as far
as possible how far the predictions of the
model match with subsequently obtained
data. We recently studied liver biopsy
specimens in 4 patients, 3 at 3 hours and
1 at 24 hours after intravenous [3H] Mtx,
and bile from another patient who had a
complete biliarv fistula and we were able
to compare observed values for hepatic
and biliarv Mtx levels with those predicted
by the model. The model predicts a liver
to plasma ratio ofapproximately 5: 1 and
preferential biliarv excretion of drug.
All patients had inoperable cancer that
was not amenable to conventional therapy
and were entering a study of the clinical
evaluation of Mtx (Selawrv, 1970); all
gave informed consent to entry into the
study. All had normal renal function as
defined by a blood urea nitrogen level of
<25 mg/100 ml and serum creatinine con-
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centration of <15 mg/100 ml. [3',5',3H]
Mtx (250 1iCi) obtained from Searle,
Amersham, was mixed with unlabelled
Mtx to a total dose of 80mg/M2 body
surface area (1-9-2-4 mg/kg body weight)
and given intravenously in a bolus. Blood
was drawn from a forearm vein, centri-
fuged and 0-1 ml of plasma assayed for
radioactivity by liquid scintillation count-
ing in a Beckman LS 250 liquid scintilla-
tion counter. Liver biopsy specimens
were blotted, weighed and solubilized in
1 ml of 1 NNaOH at 600 for 1 hour, BBS2
(Beckman Instrument Co. Fullerton, Cali-
fornia) was added as described by Pollay
and Stevens (1970) and the solution
counted. Bile was counted in the same
way as for plasma. No significant meta-
bolism of Mtx occurs and the compound
is recovered unchanged in the urine.
Urine recovery of unchanged Mtx in the
present study was 76-88o of the dose,
mainly in the first 24 hours. Total
radioactivity may therefore be taken as a
measure of MItx.
The liver biopsy results are shown in
the Table. In spite of the inherent
liability to error in the method, the ratio
at 3 hours is surprisingly close to that
predicted, even though the dose of Mtx
studied (dictated by the clinical study
protocol) was higher than that for which
the prediction was made (1 mg/kg) by the
model. The model does not predict
beyond 6 hours so it is not possible to test
the value obtained at 24 hours against it
directly. The Mtx level in a metastatic
tumour lesion in the liver in one patient
did not show preferential uptake. The
data on biliarv excretion, however (Fig. 1),
clearly indicate that in the patient studied
there is no tendency for preferential
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FIG. 1. Mlethotrexate in plasma and bile after
intravenous administration.
TABLE. Methotrexate in Liver Followving Intrareno is Administration
Patient
EB
JJ
JR
[JR++
DC
Notes
Age Diagnosis
64 Epidermoid carcinoma floor of mouth
42 Epidermoid carcinoma tongue
48 Epidermoid carcinoma unknown primary
55 Carcinoma-sarcoma pyriform sinus
Liver 'Itx
7-35*
4.61*
6-10±
1-23t
0-72t
Plasma MNtx
ILgml
1-55
1-10
1-46
1-46
0-09
Liver
plasma$
ratio
4 7
4-2
4-2
0-84
8-0
TiLme
post-
infusion
hours
3
3
3
3] 24
* Liver obtained bv closed biopsy using a Menghini needle.
t Liver obtained bv biopsy using a modified VIim-Silverman needle under direct vision bv peritoneoscopy.
+ Tumour tissue metastatic to the liver obtained simultaneously With surrounding normal liver.
§ Plasma (0 1 ml) was counted in a liquid scintillation counter in 15 ml of toluene containing PPO 6 g and
BBS3 (Beckman Instrument Co.) 100 g l.
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biliarv excretion of Mtx. Bile levels are
lower than plasma levels throughout the
24 hours of measurement. Total recovery
of Mtx in bile was 0-4100 of the
administered dose in the first 48 hours.
which can be accounted for by diffusion
throughout body water.
The reason for the high concentrations
of methotrexate in the liver are not
known. Our data suggest that the com-
pound is not excreted in the bile in man.
Methotrexate binds essentially irrever-
siblv to the enzvme dihydrofolate reduc-
tase (Futterman, 1957; Osborn, Freeman
and Huennekens, 1958), an enzyme which
is known to have high levels in the liver in
animals (Hall, Roberts and Kessel, 1966).
However, levels of this enzyme in human
tissues including liver are less than 0-08
nmol Mtx equivalentfIg tissue. Binding
to dihvdrofolate reductase could therefore
account for less than 100 of the total Mtx
found at 3 hours and about 5O% of that
found at 24 hours. Binding to dihydro-
folate reductase cannot therefore account
for the high concentrations seen in the liver
in the present study.
The preliminary data presented here
indicate the need for further human
studies to check in man the elaborate
pharmacokinetic models derived from
animal data, in order to determine how far
such models reliablv predict for man.
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